Megan Mackey

5.8k total citations · 3 hit papers
44 papers, 4.7k citations indexed

About

Megan Mackey is a scholar working on Molecular Biology, Electronic, Optical and Magnetic Materials and Genetics. According to data from OpenAlex, Megan Mackey has authored 44 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Electronic, Optical and Magnetic Materials and 12 papers in Genetics. Recurrent topics in Megan Mackey's work include Gold and Silver Nanoparticles Synthesis and Applications (13 papers), Glioma Diagnosis and Treatment (12 papers) and Nanoplatforms for cancer theranostics (8 papers). Megan Mackey is often cited by papers focused on Gold and Silver Nanoparticles Synthesis and Applications (13 papers), Glioma Diagnosis and Treatment (12 papers) and Nanoplatforms for cancer theranostics (8 papers). Megan Mackey collaborates with scholars based in United States, Pakistan and United Kingdom. Megan Mackey's co-authors include Mostafa A. El‐Sayed, Erik C. Dreaden, Bin Kang, Lauren A. Austin, Xiaohua Huang, Kevin Camphausen, John A. Butman, Teri Kreisl, Lyndon Kim and Howard A. Fine and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Chemical Society Reviews.

In The Last Decade

Megan Mackey

42 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

2008 1.2k citations Megan Mackey, John A. Butman et al. profile →
Nuclear Targeting of Gold Nanoparticles in Cancer Cells Induces DNA Damage, Causing Cytokinesis Arrest and Apoptosis

2010 532 citations Bin Kang, Megan Mackey et al. profile →
Size Matters: Gold Nanoparticles in Targeted Cancer Drug Delivery

2012 501 citations Erik C. Dreaden, Lauren A. Austin et al. profile →

Peers

Countries citing papers authored by Megan Mackey

Since Specialization

Citations

This map shows the geographic impact of Megan Mackey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megan Mackey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megan Mackey more than expected).

Fields of papers citing papers by Megan Mackey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megan Mackey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megan Mackey. The network helps show where Megan Mackey may publish in the future.

Co-authorship network of co-authors of Megan Mackey

This figure shows the co-authorship network connecting the top 25 collaborators of Megan Mackey. A scholar is included among the top collaborators of Megan Mackey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megan Mackey. Megan Mackey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MGMT ProFWise: Unlocking a New Application for Combined Feature Selection and the Rank-Based Weighting Method to Link MGMT Methylation Status to Serum Protein Expression in Patients with Glioblastoma 2024 ·International Journal of Molecular Sciences ·Erdal Taşçı, Yajas Shah, (unknown), Ying Zhuge, (unknown), Margaret Johnson, Olivier Elemento, (unknown), (unknown), (unknown), Mary Sproull, Megan Mackey, Kevin Camphausen, Andra Krauze	6
2	MetaWise: Combined Feature Selection and Weighting Method to Link the Serum Metabolome to Treatment Response and Survival in Glioblastoma 2024 ·International Journal of Molecular Sciences ·Erdal Taşçı, (unknown), Ying Zhuge, (unknown), Longze Zhang, (unknown), Mary Sproull, Megan Mackey, Heather R. Kates, Timothy J. Garrett, Kevin Camphausen, Andra Krauze	4
3	Evaluating Serum CXCL Levels as Potential Biomarkers in Glioblastoma: Observed Alteration with Concurrent Chemoirradiation in Upfront Management 2024 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mary Sproull, Megan Mackey, Kevin Camphausen, Andra Krauze	1
4	Radiographic calibration for pubic diastasis assessment in bladder exstrophy-epispadias complex: a phantom study 2024 ·Pediatric Radiology ·Susan J. Back, (unknown), (unknown), Esmaeil Akbari, Megan Mackey, Elanor C. Hinton, D. B. HORN, Martin Kidd, Michael L. Francavilla	0
5	Glioblastoma survival is associated with distinct proteomic alteration signatures post chemoirradiation in a large-scale proteomic panel 2023 ·Frontiers in Oncology ·Andra Krauze, Michael Sierk, (unknown), Qingrong Chen, Chunhua Yan, Ying Hu, (unknown), Erdal Taşçı, (unknown), Mary Sproull, Megan Mackey, Uma Shankavaram, Daoud Meerzaman, Kevin Camphausen	7
6	RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma 2023 ·Cancers ·Erdal Taşçı, (unknown), Ying Zhuge, Mary Sproull, (unknown), Megan Mackey, Kevin Camphausen, Andra Krauze	10
7	Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma—Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation 2023 ·Biomolecules ·Andra Krauze, Yingdong Zhao, Ming‐Chung Li, Joanna H. Shih, (unknown), Erdal Taşçı, (unknown), Mary Sproull, Megan Mackey, Uma Shankavaram, Philip J. Tofilon, Kevin Camphausen	7
8	Development and qualification of an automated capillary Western method for the identification of polysaccharide serotypes in pneumococcal conjugate vaccine (PCV) 2023 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), John W. Loughney, Richard R. Rustandi, (unknown), Megan Mackey	1
9	A Serum Proteomic Signature Predicting Survival in Patients with Glioblastoma 2020 ·PubMed ·Mary Sproull, (unknown), (unknown), Megan Mackey, Thomas Cooley, Dee Dee Smart, Uma Shankavaram, Kevin Camphausen	4
10	Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma 2019 ·Neuro-Oncology Practice ·(unknown), Lindsay Rowe, Megan Mackey, Dee Dee Smart, Philip J. Tofilon, Kevin Camphausen	16
11	Exploration of long-acting implant formulations of hepatitis B drug entecavir 2019 ·European Journal of Pharmaceutical Sciences ·(unknown), Stephanie E. Barrett, Seth Forster, Ryan S. Teller, (unknown), Li Li, Megan Mackey, (unknown), (unknown), (unknown), Lee J. Klein, Marian E. Gindy	15
12	Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM 2018 ·Journal of Neuro-Oncology ·Lindsay Rowe, John A. Butman, Megan Mackey, Joanna H. Shih, (unknown), Holly Ning, Mark R. Gilbert, Dee Dee Smart, Kevin Camphausen, Andra Krauze	29
13	Mixed Reality Meets Pharmaceutical Development 2017 ·Journal of Pharmaceutical Sciences ·William P. Forrest, Megan Mackey, Vivek M. Shah, (unknown), Prashant Shah, (unknown), (unknown), (unknown), Li Li, W. Peter Wuelfing, Roy Helmy	3
14	In vitro investigations of gold nanocages: Toxicological profile in human keratinocyte cell line 2016 ·Food and Chemical Toxicology ·Farhat Saira, Megan Mackey, Rumana Qureshi, Mahmoud A. Mahmoud	2
15	The optical, photothermal, and facile surface chemical properties of gold and silver nanoparticles in biodiagnostics, therapy, and drug delivery 2014 ·Archives of Toxicology ·Lauren A. Austin, Megan Mackey, Erik C. Dreaden, Mostafa A. El‐Sayed	355
16	Antimicrobial Activity of Water‐Soluble Triazole Phenazine Clickamers against E. coli 2013 ·Chemistry - A European Journal ·Steven C. Hayden, (unknown), Megan Mackey, Katharina Höfer, Benjamin Lindner, Vanessa P. Nguyen, Andres Jäschke, Uwe H. F. Bunz	6
17	Beating cancer in multiple ways using nanogold 2011 ·Chemical Society Reviews ·Erik C. Dreaden, Megan Mackey, Xiaohua Huang, Bin Kang, Mostafa A. El‐Sayed	498
18	Comparative study of photothermolysis of cancer cells with nuclear-targeted or cytoplasm-targeted gold nanospheres: continuous wave or pulsed lasers 2010 ·Journal of Biomedical Optics ·Xiaohua Huang, Bin Kang, Wei Qian, Megan Mackey, Po C. Chen, Adegboyega K. Oyelere, Ivan H. El‐Sayed, Mostafa A. El‐Sayed	91
19	A novel antagonist of the prostaglandin E₂ EP₄ receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models 2010 ·British Journal of Pharmacology ·(unknown), Kazuyo Muramoto, (unknown), Yinlu Ding, Hua Yang, Megan Mackey, (unknown), Yoko Inoue, Karen Ackermann, Hiroshi Shirota, Isao Matsumoto, Mark R. Spyvee, (unknown), Takayuki Sumida, Fabian Gusovsky, Marc S. Lamphier	84
20	Increase in Hybridization Rates with Oligodeoxyribonucleotides Containing Locked Nucleic Acids 2006 ·Journal of Biomolecular Structure and Dynamics ·Thomas K. Ormond, (unknown), (unknown), Megan Mackey, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact